香港復發性卵巢癌的藥物基因組學研究


Affordable Multi-gene Mutation-drug Matching for Recurrent Ovarian Cancer Patients in Hong Kong

Find out more

Ovarian Cancer in Hong Kong


Cancer of the ovary is the 6th most common female genital tract cancer and 7th in mortality rate in Hong Kong (Hong Kong Cancer Registry 2015). There were 578 new cases and 214 deaths due to ovarian cancer in 2015. In advanced ovarian cancer, albeit radical treatment, recurrence is common and can be up to 70-80% in stage III or IV ovarian cancer.

Although there are quite a number of drugs that can be used for recurrent ovarian cancers, we do not know which one has the best response. Thus, a patient will be receiving one drug after another when resistance occurs.

We need a more precise way of choosing the most effective drug(s) based on individual’s tumor characteristics.

About us

What are we doing in this study?


Pharmacogenomic analysis can help identify a more precise choice of drug based on the tumour DNA characteristics of a patient. In this research study, we would like to determine the frequency of occurrences of potential mutations that are linked to drug responses in ovarian cancer patients in Hong Kong. At the same time, we will provide a pharmacogenomics research results based on our drug-responder genomic database.

The analysis first requires tumour DNA to be sequenced for multiple genes, which have been reported to be related to drug responses, followed by professional DNA (mutation)-drug matching based on our drug-responder genomic database curated from scientific publications.

Aims

Aims


To provide free multi-gene pharmacogenomic analysis with drug-matching for 100 recurrent ovarian cancer patients in Hong Kong (The period of this study is from December of 2017 to September of 2020; a target of 25 patients every 4 months).

To help identify a more precise choice of drug based on tumour DNA characteristics using modern pharmacogenomic analysis. At the same time, the research team will determine the prevalence of potential druggable DNA events in Asian recurrent ovarian cancer patients.

Participation


You are welcome to participate in this study if:

1. You are a Hong Kong permanent resident with recurrent ovarian cancer.
2. Your ovarian cancer is failing current or at least a first-line chemotherapy.
3. You are ready to share your pathology report and evidence for failing current therapy.
4. You are willing to provide your family history of cancer.
5. You are willing to participate this pharmacogenomics DNA test by signing patient consents.
6. You will receive your physician’s agreement to provide your surgical tumor DNA sample. You will be willing to provide your tumor samples and blood sample for this study.
7. You are willing to be followed-up with phone calls on your progress every 4-6 months by phone calls from us.
8. You agree that our research group has the right to analyse your DNA sequences for research purposes.

Multi-gene Sequencing Analysis of Your Tumor Samples


Patients can provide us with your tumor samples, which will be subjected to advanced multi-gene sequencing using our clinical Responder Gene Panel. The Panel includes all reported ovarian cancer patient DNA mutations that are associated with good & exceptional clinical responses to specific drug treatments in ovarian cancer patients as of 2017. Our team has established this responder genetic database for developing pharmacogenomics and precision medicine.

Using this responder genetic database, our team has designed a responder multi-gene platform, called the Responder Gene Panel, for Next-Generation Sequencing (NGS) for pharmacogenomic analysis of patient tumour samples in Hong Kong.
The Responder Gene Panel is composed of two parts. Part I of the Responder Gene Panel contains all reported ovarian cancer patient DNA mutations known to be associated with good & exceptional clinical responses to specific drug treatments as of 2017. Any enrolled ovarian cancer patients whose tumors carry these responder DNA mutations will be informed by our team. We will follow-up on the patient/doctor drug choice in this first Hong Kong pharmacogenomic research study.

For research purposes, part II of this Responder Gene Panel contains additional gene mutations that have been reported in clinical responders from all other cancer types as of 2017. Any enrolled ovarian cancer patients whose tumors carry these responder DNA mutations will be informed by our team. Using this part of the Responder Gene Panel, we will determine the rate of occurrence of these potential druggable mutations in recurrent ovarian cancer in Hong Kong. Results from this part can help us quickly identify key genes to be further studied in ovarian cancer drug research.

Our Research Team




Principal Investigators


Prof. Vivian Wai Yan LUI
Associate Professor,
School of Biomedical Sciences,
CUHK,
Hong Kong
Prof. Hextan Yuen-Sheung NGAN
Department Chair and Professor,
Department of Obstetrics and Gynaecology,
HKU,
Hong Kong
Prof. Stephen Kwok Wing TSUI
Professor,
School of Biomedical Sciences,
CUHK,
Hong Kong


Co-Investigators


Dr. Karen Kar Leon Chan
Clinical Associate Professor,
Department of Obstetrics & Gynaecology,
Queen Mary Hospital,
Hong Kong
Dr. Siew Fei Ngu
Clinical Assistant Professor,
Department of Obstetrics & Gynaecology,
Queen Mary Hospital,
Hong Kong
Dr. Mandy Man Yee Chu
Associate Consultant,
Department of Obstetrics & Gynaecology,
Queen Mary Hospital,
Hong Kong
Dr. Ka Yu Tse
Consultant,
Queen Mary Hospital,
Hong Kong
Dr. David Wai Chan
Assistant Professor,
Department of Obstetrics & Gynaecology,
Queen Mary Hospital,
Hong Kong
Prof. Ian Chi Kei Wong
Professor,
Pharmacy Practice and,
Head of the Research Department of Practice and Policy,
University College of London,
London, UK

Professor,
Department of Pharmacology & Pharmacy,
HKU,
Hong Kong
Prof. Alfred Sze Lok Cheng
Professor,
School of Biomedical Sciences,
CUHK,
Hong Kong
Mr. Henry Yau
Managing director,
Clinical Trials centre,
Hong Kong


Overseas Consultant


Prof. Gordon B. Mills
Department Chair,
Department of Systems Biology,
Division of Basic Science Research,
The University of Texas MD Anderson Cancer Center,
Houston,
TX,
USA

FAQ


Do I need to pay for this study?

No. The gene sequencing and mutation-drug matching will be provided at no cost to all eligible participants.

Please note that cost may only incur to you when you request your tumor DNA samples from your hospital. This specimen request cost will not be provided by this study.

How can I participate in the study?

We invite all interested participant to call us at 3943-5382 during working hours (Mon-Fri, 9:00 am-5:00 pm) to go through an eligibility check and a simple pre-study counseling by our team.

Will my participation affect the treatment I am receiving currently?

No, the treatment you are receiving is directly provided by your doctor. With this mutation drug-matching study, we will inform you if your tumors contain drug response-related mutations. You and your physician have the full right to decide to use or not to use this pharmacogenomics information for your future treatment.

How can I benefit from this study?

You will benefit from free and professional pharmacogenomic multi-gene DNA test, with professional mutation-drug matching results. This service is very costly in private sector.

You will find out if your tumor sample contains any known responder mutations according to previous clinical ovarian cancer responder genetic information. This may help your doctor to find a good matching drug if there is no more treatment option for your recurrent ovarian cancer.

Will there be additional invasive intervention involved?

No. Your tumor sample has already been previously collected during your ovarian caner surgery. No additional surgery will be required. Once again to participate in this study, you will be requested to provide your blood sample (5-10 ml) as control for your tumor DNA sequencing.

Can I withdraw from the study time?

Yes. The participation is entirely voluntary, and you have the possibility to withdraw your consent at any time without the need to give any reason and this decision will not affect the treatment that you will receive.

How will the personal data be handled during and after the study?

Your personal information will be de-identified in the entire study. All samples and information provided by you will be kept in strict confidentiality. We will only use your personal contacts for our follow-up every 4-6 months for 2 years. All your personal information are required to be destroyed 7 years after the study.

Who will have access to the personal data during and after the study?

The research team and the doctors in the study will have such an access for research purpose only, when necessary.

Sponsorship


The study is generously sponsored by Hong Kong Cancer Fund

Hong Kong Cancer Fund

Established in 1987, our vision was to better the quality of cancer support in Hong Kong and ensure that no one faces cancer alone. We began by offering free information and support to anyone touched by cancer, which has slowly expanded over time to address all aspects of living with cancer. Our work now encompasses public education, cancer research, home care, peer support, complementary therapies, funding of hospital equipment and much more in filling the gaps in cancer care and making life better for people touched by cancer.

For Enquiry


Please do not hesitate to call us during office hour: Mon-Fri: 9:00 am to 5:00 pm,
or send us an email.

+852 3943 5382